Tumor ablation is evolving from a local cytoreductive technique into a reproducible in situ vaccination platform; by ensuring procedural completeness, integrating immune checkpoint blockade or innate agonists—particularly in settings with cGAS–STING pathway suppression such as RECQL4-high HCC or TRIM6-high MSS gastric cancer—and embedding a robust biomarker framework, the abscopal effect can be transformed from a rare anecdote into predictable systemic immunity, positioning ablation as a cornerstone of next-generation cancer immunotherapy. The gene discussed is CGAS; the disease is hepatocellular carcinoma.